Immunovant Announces $550 Million Stock Offering

Immunovant ( (IMVT) ) has issued an announcement.

On December 10, 2025, Immunovant announced the pricing of an underwritten offering of its common stock, expected to raise approximately $550 million. The proceeds are anticipated to fund operations through the potential commercial launch of IMVT-1402 for Graves’ Disease. The company is advancing its clinical programs, including a potentially registrational trial for IMVT-1402 in rheumatoid arthritis, with results expected in 2026. However, the company faces challenges, including potential disputes with HanAll over rights to batoclimab, and the inherent risks and uncertainties of clinical trials.

The most recent analyst rating on (IMVT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Immunovant stock, see the IMVT Stock Forecast page.

Spark’s Take on IMVT Stock

According to Spark, TipRanks’ AI Analyst, IMVT is a Neutral.

Immunovant’s stock score is primarily impacted by substantial financial weaknesses, including ongoing losses and cash flow issues. Technical indicators are bearish, further weighing on the stock’s attractiveness. However, recent positive clinical trial results and leadership changes provide some optimism, potentially strengthening the company’s pipeline and long-term prospects.

To see Spark’s full report on IMVT stock, click here.

More about Immunovant

Immunovant, Inc. operates in the biotechnology industry, focusing on the development of innovative therapies for autoimmune diseases. The company is working on IMVT-1402, a potential first- and best-in-class anti-FcRn therapy, targeting multiple indications including Graves’ Disease, difficult-to-treat rheumatoid arthritis, and others.

Average Trading Volume: 1,676,431

Technical Sentiment Signal: Buy

Current Market Cap: $3.99B

Find detailed analytics on IMVT stock on TipRanks’ Stock Analysis page.